SMTL ID : 6bft.1

Structure of Bevacizumab Fab mutant in complex with VEGF

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.55 Å

Oligo State

hetero-2-2-2-mer

Ligands

2 x SO4: SULFATE ION(Non-functional Binders)

SO4.1: 4 residues within 4Å: Chain A: Q.37, K.39, K.42, K.45 3 PLIP interactions: 3 interactions with chain A Salt bridges: A:K.39, A:K.42, A:K.45 SO4.2: 4 residues within 4Å: Chain C: Q.37, K.39, K.42, K.45 4 PLIP interactions: 4 interactions with chain C Hydrogen bonds: C:Q.37 Salt bridges: C:K.39, C:K.42, C:K.45

2 x MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID(Non-covalent)

MES.3: 6 residues within 4Å: Chain D: Y.54 Chain E: Y.14, Q.15, Y.18, N.55 Ligands: MES.4 1 PLIP interactions: 1 interactions with chain E pi-Cation interactions: E:Y.14 MES.4: 7 residues within 4Å: Chain D: D.30, T.53, Y.54, T.55, G.56, T.74 Ligands: MES.3 1 PLIP interactions: 1 interactions with chain D Hydrogen bonds: D:Y.54

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Christie, M. et al., Stable human IgG antibody therapeutics with native framework structure. To Be Published

Release Date

2018-10-31

Peptides

Avastin Light Chain Fab fragment mutant: AC
Avastin Heavy Chain Fab fragment mutant: BD
Vascular endothelial growth factor A: EF

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

C
L

B
A

D
H

E
G

F
C

Avastin Light Chain Fab fragment mutant

Avastin Heavy Chain Fab fragment mutant

Vascular endothelial growth factor A